Prioritizing Therapeutics for Lung Cancer: An Integrative Meta-analysis of Cancer Gene Signatures and Chemogenomic Data

Repurposing FDA-approved drugs with the aid of gene signatures of disease can accelerate the development of new therapeutics. A major challenge to developing reliable drug predictions is heterogeneity. Different gene signatures of the same disease or drug treatment often show poor overlap across stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortney, Kristen, Griesman, Joshua, Kotlyar, Max, Pastrello, Chiara, Angeli, Marc, Sound-Tsao, Ming, Jurisica, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364883/
https://www.ncbi.nlm.nih.gov/pubmed/25786242
http://dx.doi.org/10.1371/journal.pcbi.1004068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364883/
https://www.ncbi.nlm.nih.gov/pubmed/25786242
http://dx.doi.org/10.1371/journal.pcbi.1004068

Ejemplares similares